Aerovate Therapeutics Inc (AVTE) - Net Assets
Based on the latest financial reports, Aerovate Therapeutics Inc (AVTE) has net assets worth $75.05 Million USD as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($77.53 Million) and total liabilities ($2.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check AVTE financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $75.05 Million |
| % of Total Assets | 96.79% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 7.09 |
Aerovate Therapeutics Inc - Net Assets Trend (2019–2024)
This chart illustrates how Aerovate Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore AVTE total assets for the complete picture of this company's asset base.
Annual Net Assets for Aerovate Therapeutics Inc (2019–2024)
The table below shows the annual net assets of Aerovate Therapeutics Inc from 2019 to 2024. For live valuation and market cap data, see market value of Aerovate Therapeutics Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $76.43 Million | -30.17% |
| 2023-12-31 | $109.46 Million | -13.64% |
| 2022-12-31 | $126.74 Million | -26.49% |
| 2021-12-31 | $172.42 Million | +1392.10% |
| 2020-12-31 | $-13.34 Million | -266.29% |
| 2019-12-31 | $-3.64 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aerovate Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 22940900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.00% |
| Other Comprehensive Income | $105.00K | 0.14% |
| Other Components | $309.38 Million | 404.76% |
| Total Equity | $76.43 Million | 100.00% |
Aerovate Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Aerovate Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Huvis Corporation
KO:079980
|
$77.73 Million |
|
PolyPid
NASDAQ:PYPD
|
$77.73 Million |
|
Pender Growth Fund VCC Inc
V:PTF
|
$77.74 Million |
|
Fairchem Organics Limited
NSE:FAIRCHEMOR
|
$77.75 Million |
|
South West Pinnacle Exploration Limited
NSE:SOUTHWEST
|
$77.61 Million |
|
SanDi Properties Co Ltd
TW:1438
|
$77.60 Million |
|
Thinkific Labs Inc
TO:THNC
|
$77.57 Million |
|
Axon Partners Group S.A.
MC:APG
|
$77.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aerovate Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 109,456,000 to 76,434,000, a change of -33,022,000 (-30.2%).
- Net loss of 69,628,000 reduced equity.
- New share issuances of 23,942,000 increased equity.
- Other comprehensive income decreased equity by 132,000.
- Other factors increased equity by 12,796,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-69.63 Million | -91.1% |
| Share Issuances | $23.94 Million | +31.32% |
| Other Comprehensive Income | $-132.00K | -0.17% |
| Other Changes | $12.80 Million | +16.74% |
| Total Change | $- | -30.17% |
Book Value vs Market Value Analysis
This analysis compares Aerovate Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.00x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.15 | $2.68 | x |
| 2020-12-31 | $-0.55 | $2.68 | x |
| 2021-12-31 | $7.06 | $2.68 | x |
| 2022-12-31 | $5.18 | $2.68 | x |
| 2023-12-31 | $4.16 | $2.68 | x |
| 2024-12-31 | $2.67 | $2.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aerovate Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -91.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.05x
- Recent ROE (-91.10%) is below the historical average (-35.68%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.97 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.70 Million |
| 2021 | -13.32% | 0.00% | 0.00x | 1.02x | $-40.20 Million |
| 2022 | -40.64% | 0.00% | 0.00x | 1.07x | $-64.19 Million |
| 2023 | -69.00% | 0.00% | 0.00x | 1.16x | $-86.47 Million |
| 2024 | -91.10% | 0.00% | 0.00x | 1.05x | $-77.27 Million |
Industry Comparison
This section compares Aerovate Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $173,740,057
- Average return on equity (ROE) among peers: -43.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aerovate Therapeutics Inc (AVTE) | $75.05 Million | 0.00% | 0.03x | $77.68 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.69 Million | 20.23% | 0.26x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $3.74 Billion |
About Aerovate Therapeutics Inc
Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts.